Access Pharmaceuticals, Inc.
(OTC:ACCP)
Many investors have raised concerns with regards to Access Pharmaceuticals being on the OTC. Indeed more than half the time companies which are not listed on a major exchange tend to lie, cheat and do just about anything possible in order to stimulate investor demand. They will reach out to stock promoters, make deals with various PR companies and even go as far as releasing their own false press 
releases — usually involving buyouts (see OTC:PGYC). Folks, you need not worry, Access Pharma takes part in none of these illegal activities in order to induce demand, rather they focus on a solid and sound business strategy which willslowly take them into the promise land. Patience is a virtue.
MuGard is an interesting product with a lot of potential, and we truly believe that it is only a matter of time before this drug gains worldwide success from the ongoing marketing campaigns.
Oral Mucosis
Oral mucositis is a frequent complication of cancer chemotherapy or radiation therapy to the head and neck region. Currently available therapy is usually inadequate, and a more effective treatment to minimize the extent and duration of mucositis is clearly needed.
-
}Mucositis can affect most patients receiving cancer therapy.
-
Addressable market estimated at over $1 billion.
-
}MuGard is polymer solution which provides coating for oral cavity.
-
}Dispensed as a ready-to-use viscous liquid.
-
}Potential expansion to other markets, such as dental market, oral surgery, etc.
Clinical Study
}
The clinical study was conducted at 11 centers.
Patients rinsed up to 6 times a day with MuGardTM during a course of radiation therapy (with or without concomitant chemotherapy) with a planned dose of at least 60 Gy over 6-7 weeks.
Patient mucositis was evaluated 3 times a week according to the Oral Mucositis Assessment Scale (OMAS), a validated assessment scale
MuGardTM data were compared with data from two similar sets of patients receiving standard care. Statistical analysis comparing the mean maximum OMAS score of the MuGardTM group to each of the untreated groups was performed using two-sided tests at the 0.05 level of significance.
42% of patients in the MuGardTM Rinse group
did not develop significant mucositis during the 6-7
week radiation treatment cycle compared with only
9% in the historical control group
Summary
- MuGard has a US 510(k) FDA marketing allowance and European CE Mark approval
- Access has recently announced agreements with SpePharm for the EU, Milestone for the US, JCOM in Korea, and RHEI for China and other Southeast Asian countries
- “Prevention” positioning yields significant sales potential and lessens the number of competitive products
- In patients receiving radiation therapy for head and neck cancer, 42% of patients using MuGard Rinse group did not develop significant mucositis compared with only 9% in a historical control group
- Simple ready to use formulation is major competitive advantage
MuGard Entering Europe (Extensive Market)
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), announced today that its European partner, SpePharm has commenced commercial launch of MuGard in Greece. This follows previous commercial launches in Germany, Italy and the UK. Under a license from Access Pharmaceuticals, SpePharm is responsible for manufacturing, regulatory approval and commercialization in the 27 countries of Europe. SpePharm plans to launch MuGard in the rest of Europe over the coming 12 to 18 months. The license agreement includes royalties on net sales to Access.
Additionally, the Company announced that two MuGardTM patents have been issued from the United States Patent and Trademark Office, as US Patent numbers 7,544,348 and 7,547,433. The second patent includes claims on formulations with actives against mucocutaneous disorders, which provides protection of product line extensions.
MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and/or radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.
MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth. In a comparison of cancer patients receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis.
Bonus Conference Call Audio with CEO, Jeffrey B. Davis
If you are experiencing technical difficulties, please visit this link. You will be taken to the original source of the mp3 file where your automatic preset media player should make the file play.
In conclusion, some persistence will go a long with with this small yet flourishing company. Yes, indeed, patience is a virtue which is all too often forgotten.
—–
Disclosure: No Positions
—–
By reading StocksHaven Investments you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence.
MuGard was touted as a $1B product already with FDA approval and Access WAS a nice investment opportunity or so it seemed until SCO (Vulture Capitalists) got involved via a very dilutive convertible note. For $4.5M Access execs turned over 80% and control of the company to SCO. Part of the deal involved SCO placing two of its people on the Access Board.
In effect Access execs sold out shareholders for a pittance. I am sure there were other financial distributions that made this a good deal for Access upper management otherwise it makes no sense at all.
Fortunately I bought in at under $2 and sold at over$10 prior to the web broadcast back in Feb ’07 when an investor asked about the SCO note and Davis pausesd stuttered and paused again and again trying to make it sound relatively harmless.
A year later it was back under 2.00 and Advaxis hadt yet to sell a jug, bottle or jar of MuGard as SCO’s deep pockets allowed them to sit on the product until the stock tumbled to where they could start buying up more shares.
At the top of your blog you state, “half the time companies which are not listed on a major exchange tend to lie, cheat and do just about anything possible in order to stimulate investor demand”. It seems Access connections have done just that in order to dry up investor demand. They have a billion dollar product and they want it all to themselves.
vengo de otra pagina y la verdad que no se entendia nada alli, muy bueno! gracias,, bien explicado!
hey!,I like yourreview so much! share we chat more about your weblog on MSN? Looking forward to see you.